DoD Peer Reviewed Medical, Clinical Trial Award | HT9425 23 PRMRP CTA

Opportunity Information: Apply for HT9425 23 PRMRP CTA

The DoD Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award (CTA), Funding Opportunity Number HT9425 23 PRMRP CTA, is a Department of Defense funding opportunity administered through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is offered as either a grant or a cooperative agreement under CFDA 12.420, within the broader category of science, technology, and research and development. The overall purpose of this mechanism is to move quickly into clinical testing by supporting the rapid launch and execution of human clinical trials that could make a meaningful difference for diseases or conditions that fall within the congressionally directed FY23 PRMRP Topic Areas and align with the FY23 PRMRP Strategic Goals.

The core requirement of this award is that the proposed work must be a clinical trial. In this context, a clinical trial is specifically defined as a prospective human study where one or more participants are assigned to one or more interventions in order to measure effects on biomedical or behavioral health outcomes. The intervention can take many forms, including an investigational product or approach and, where appropriate, may include a placebo or other control arm. In practical terms, applications need to be built around a true interventional trial design rather than observational research, retrospective analyses, or studies that do not prospectively assign participants to an intervention.

The CTA is designed to cover a wide range of clinical trial stages and sizes. At the early end, it can support smaller proof-of-concept efforts such as pilot studies, first-in-human trials, or phase 0 trials, especially when the goal is to demonstrate feasibility, generate preliminary human data, or refine the design for a subsequent larger trial. At the more advanced end, it can also support larger-scale trials intended to determine efficacy in relevant patient populations. This breadth signals that the program is not limited to a single phase of development; instead, it prioritizes trials that are ready to be implemented and that can credibly deliver results with potential for significant impact.

In terms of what can be tested, the program is intentionally broad and translational. Eligible trial concepts may evaluate promising new medical products, pharmacologic agents (including drugs and biologics), medical devices, clinical guidance or care approaches, and emerging approaches or technologies. That scope allows applicants to propose trials that translate earlier research into practical interventions, whether the intervention is a tangible product like a device or therapeutic agent, or a structured clinical practice change intended to improve outcomes.

Eligibility is listed as unrestricted, meaning it is open to any type of applicant entity, subject to any additional eligibility clarifications that may appear in the full opportunity text. The opportunity was posted (creation date) January 31, 2023, with an original closing date of July 19, 2023. The listing notes an expected number of awards of 9. The award ceiling is shown as 0 in the summary data, which typically indicates that applicants must rely on the full announcement for detailed budget limits or that the ceiling is not specified in the simplified record.

Overall, this opportunity is best understood as a DoD mechanism meant to accelerate human clinical testing in PRMRP priority areas, with funding specifically tied to conducting an interventional clinical trial and generating outcome-focused evidence that could drive meaningful advances in prevention, diagnosis, treatment, or clinical management of the targeted conditions.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Peer Reviewed Medical, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jan 31, 2023.
• Applicants must submit their applications by Jul 19, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 9 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 PRMRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: